Mannan-Decorated Lipid Calcium Phosphate Nanoparticle Vaccine Increased the Antitumor Immune Response by Modulating the Tumor Microenvironment
Source abstract
Abstract
With the rapid development of tumor immunotherapy, nanoparticle vaccines have attracted much attention as potential therapeutic strategies. A systematic review and analysis must be carried out to investigate the effect of mannose modification on the immune response to nanoparticles in regulating the tumor microenvironment, as well as to explore its potential clinical application in tumor therapy. Despite the potential advantages of nanoparticle vaccines in immunotherapy, achieving an effective immune response in the tumor microenvironment remains a challenge. Tumor immune escape and the overexpression of immunosuppressive factors limit its clinical application. Therefore, our review explored how to intervene in the immunosuppressive mechanism in the tumor microenvironment through the use of mannan-decorated lipid calcium phosphate nanoparticle vaccines to improve the efficacy of immunotherapy in patients with tumors and to provide new ideas and strategies for the field of tumor therapy.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Immunotherapy and Immune Responses · RNA Interference and Gene Delivery · Cancer Immunotherapy and Biomarkers
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Center of Hepatobiliary Pancreatic Disease, Beijing Tsinghua Changgung Hospital, School of Medicine, Tsinghua University, Beijing 100084, China
Yong Loo Lin School of Medicine, National University of Singapore, Singapore 19077, Singapore
Funding
China Scholarship Council · Scientific Research Project of the Education Department of Anhui Province · Research and Development of Intelligent Surgical Navigation and Operating System for Precise Liver Resection · Tsinghua University
References (100+)
Show source-provided references
1. Lipid-coated calcium phosphate nanoparticle and beyond: A versatile platform for drug delivery10.1080/1061186X.2017.1419360 ↗
2. Lipid-coated calcium phosphate nanoparticles for nonviral gene therapy10.1016/B978-0-12-800148-6.00007-9 ↗
3. Oridonin-loaded lipid-coated calcium phosphate nanoparticles: Preparation, characterization, and application in A549 lung cancer10.1080/10837450.2022.2090958 ↗
4. Favarin, B.Z., Bolean, M., Ramos, A.P., Magrini, A., Rosato, N., Millán, J.L., Bottini, M., Costa-Filho, A.J., and Ciancaglini, P. (2020). Lipid composition modulates ATP hydrolysis and calcium phosphate mineral propagation by TNAP-harboring proteoliposomes. Arch. Biochem. Biophys., 691.10.1016/j.abb.2020.108482 ↗
5. Current and Future Theranostic Applications of the Lipid-Calcium-Phosphate Nanoparticle Platform10.7150/thno.14689 ↗
6. Lipid-coated nano-calcium-phosphate (LNCP) for gene delivery10.1016/j.ijpharm.2010.03.012 ↗
7. Dexamethasone-Loaded Lipid Calcium Phosphate Nanoparticles Treat Experimental Colitis by Regulating Macrophage Polarization in Inflammatory Sites10.2147/IJN.S442369 ↗
8. Cruz MA, E., Ferreira, C.R., Tovani, C.B., de Oliveira, F.A., Bolean, M., Caseli, L., Mebarek, S., Millán, J.L., Buchet, R., and Bottini, M. (2020). Phosphatidylserine controls calcium phosphate nucleation and growth on lipid monolayers: A physicochemical understanding of matrix vesicle-driven biomineralization. J. Struct. Biol., 212.10.1016/j.jsb.2020.107607 ↗
9. Tang, J., Li, B., Howard, C.B., Mahler, S.M., Thurecht, K.J., Wu, Y., Huang, L., and Xu, Z.P. (2019). Multifunctional lipid-coated calcium phosphate nanoplatforms for complete inhibition of large triple negative breast cancer via targeted combined therapy. Biomaterials, 216.10.1016/j.biomaterials.2019.119232 ↗
10. Biodegradable calcium phosphate nanoparticle with lipid coating for systemic siRNA delivery10.1016/j.jconrel.2009.11.008 ↗
11. Doxorubicin-Loaded Carbon Dots Lipid-Coated Calcium Phosphate Nanoparticles for Visual Targeted Delivery and Therapy of Tumor10.2147/IJN.S229154 ↗
12. Application of a lipid-coated hollow calcium phosphate nanoparticle in synergistic co-delivery of doxorubicin and paclitaxel for the treatment of human lung cancer A549 cells10.2147/IJN.S140957 ↗
13. Calcium phosphate composite layers for surface-mediated gene transfer10.1016/j.actbio.2012.02.003 ↗
14. Sialic acid-modified dexamethasone lipid calcium phosphate gel core nanoparticles for target treatment of kidney injury10.1039/D0BM00581A ↗
15. Calcium phosphate nanoparticles with an asymmetric lipid bilayer coating for siRNA delivery to the tumor10.1016/j.jconrel.2011.10.020 ↗
16. Lipid-calcium phosphate nanoparticles for delivery to the lymphatic system and SPECT/CT imaging of lymph node metastases10.1016/j.biomaterials.2014.02.030 ↗
17. In vivo synergistic anti-tumor effect of lumefantrine combined with pH responsive behavior of nano calcium phosphate based lipid nanoparticles on lung cancer
18. Spray-congealed solid lipid microparticles as a new tool for the controlled release of bisphosphonates from a calcium phosphate bone cement
19. Calcium/phosphate-induced immobilization of fluorescent phosphatidylserine in synthetic bilayer membranes: Inhibition of lipid transfer between vesicles10.1021/bi00356a044 ↗
20. Designed Synthesis of Lipid-Coated Polyacrylic Acid/Calcium Phosphate Nanoparticles as Dual pH-Responsive Drug-Delivery Vehicles for Cancer Chemotherapy10.1002/chem.201700060 ↗
21. Mineralization of annexin-5-containing lipid-calcium-phosphate complexes: Modulation by varying lipid composition and incubation with cartilage collagens10.1074/jbc.M706523200 ↗
22. Identification of different lipid phases and calcium phosphate deposits in human carotid artery plaques by MAS NMR spectroscopy10.1002/mrm.1910390204 ↗
23. Influence of polyethylene glycol density and surface lipid on pharmacokinetics and biodistribution of lipid-calcium-phosphate nanoparticles10.1016/j.biomaterials.2013.12.022 ↗
24. Enhanced delivery of siRNA to triple negative breast cancer cells in vitro and in vivo through functionalizing lipid-coated calcium phosphate nanoparticles with dual target ligands10.1039/C7NR08644J ↗
25. Membrane-mediated precipitation of calcium phosphate in model liposomes with matrix vesicle-like lipid composition10.1016/0169-6009(92)90881-D ↗
26. Stable expression of heterologous multisubunit protein complexes established by calcium phosphate- or lipid-mediated cotransfection10.1016/0076-6879(92)07028-M ↗
27. Modulation of Alendronate release from a calcium phosphate bone cement: An in vitro osteoblast-osteoclast co-culture study10.1016/j.ijpharm.2018.11.023 ↗
28. Oncolytic Adenovirus Complexes Coated with Lipids and Calcium Phosphate for Cancer Gene Therapy10.1021/acsnano.6b06182 ↗
29. Lipid-calcium-phosphate spherules in chondrocytes of developing long bones10.1097/00003086-197107000-00019 ↗
30. pH responsive delivery of lumefantrine with calcium phosphate nanoparticles loaded lipidic cubosomes for the site specific treatment of lung cancer10.1016/j.chemphyslip.2019.03.016 ↗
31. Ke, C.H., Chiu, Y.H., Huang, K.C., and Lin, C.S. (2022). Exposure of Immunogenic Tumor Antigens in Surrendered Immunity and the Significance of Autologous Tumor Cell-Based Vaccination in Precision Medicine. Int. J. Mol. Sci., 24.10.3390/ijms24010147 ↗
32. Intravenous heterologous prime-boost vaccination activates innate and adaptive immunity to promote tumor regression10.1016/j.celrep.2023.112599 ↗
33. Coimmunomodulation of tumor and tumor-draining lymph nodes during in situ vaccination promotes antitumor immunity10.1172/jci.insight.146608 ↗
34. Mehdizadeh, R., Shariatpanahi, S.P., Goliaei, B., and Rüegg, C. (2023). Targeting myeloid-derived suppressor cells in combination with tumor cell vaccination predicts anti-tumor immunity and breast cancer dormancy: An in silico experiment. Sci. Rep., 13.10.1038/s41598-023-32554-z ↗
35. Synergistic cancer immunotherapy combines MVA-CD40L induced innate and adaptive immunity with tumor targeting antibodies10.1038/s41467-019-12998-6 ↗
36. Low-Dose Radiation Potentiates the Propagation of Anti-Tumor Immunity against Melanoma Tumor in the Brain after In Situ Vaccination at a Tumor outside the Brain10.1667/RADE-20-00237.1 ↗
37. Kim, N.J., Yoon, J.H., Tuomi, A.C., Lee, J., and Kim, D. (2023). In-situ tumor vaccination by percutaneous ablative therapy and its synergy with immunotherapeutics: An update on combination therapy. Front. Immunol., 14.10.3389/fimmu.2023.1118845 ↗
38. Varypataki, E.M., Hasler, F., Waeckerle-Men, Y., Vogel-Kindgen, S., Høgset, A., Kündig, T.M., Gander, B., Halin, C., and Johansen, P. (2019). Combined Photosensitization and Vaccination Enable CD8 T-Cell Immunity and Tumor Suppression Independent of CD4 T-Cell Help. Front. Immunol., 10.10.3389/fimmu.2019.01548 ↗
39. Administration of embryonic stem cells generates effective antitumor immunity in mice with minor and heavy tumor load10.1007/s00262-010-0899-9 ↗
40. Vaccination with vascular progenitor cells derived from induced pluripotent stem cells elicits antitumor immunity targeting vascular and tumor cells10.1007/s00262-014-1531-1 ↗
41. Adequate antigen availability: A key issue for novel approaches to tumor vaccination and tumor immunotherapy10.1007/s11481-012-9423-7 ↗
42. Vaccination with Tumor-Ganglioside Glycomimetics Activates a Selective Immunity that Affords Cancer Therapy10.1016/j.chembiol.2019.03.018 ↗
43. Microenvironment-driven metabolic adaptations guiding CD8+ T cell anti-tumor immunity10.1016/j.immuni.2022.12.008 ↗
44. Immunity to SARS-CoV-2 induced by infection or vaccination10.1111/joim.13372 ↗
45. mRNA-LNP vaccines tuned for systemic immunization induce strong antitumor immunity by engaging splenic immune cells10.1016/j.ymthe.2022.07.007 ↗
46. Schetters, S.T.T., Li, R.J.E., Kruijssen, L.J.W., Engels, S., Ambrosini, M., Garcia-Vallejo, J.J., Kalay, H., Unger, W.W.J., and van Kooyk, Y. (2020). Adaptable antigen matrix platforms for peptide vaccination strategies and T cell-mediated anti-tumor immunity. Biomaterials, 262.10.1016/j.biomaterials.2020.120342 ↗
47. HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010–201910.1016/j.ypmed.2020.106399 ↗
48. Self-Assembled Nanofibers Elicit Potent HPV16 E7-Specific Cellular Immunity And Abolish Established TC-1 Graft Tumor10.2147/IJN.S214525 ↗
49. Linked CD4+/CD8+ T cell neoantigen vaccination overcomes immune checkpoint blockade resistance and enables tumor regression10.1172/JCI164258 ↗
50. Liposomal Delivery of an Immunostimulatory CpG Induces Robust Antitumor Immunity and Long-Term Immune Memory by Reprogramming Tumor-Associated Macrophages10.1002/adhm.202300549 ↗
51. Identification of pan-cancer/testis genes and validation of therapeutic targeting in triple-negative breast cancer: Lin28a-based and Siglece-based vaccination induces antitumor immunity and inhibits metastasis10.1136/jitc-2023-007935 ↗
52. In Situ Tumor Vaccination with Calcium-Linked Degradable Coacervate Nanocomplex Co-Delivering Photosensitizer and TLR7/8 Agonist to Trigger Effective Anti-Tumor Immune Responses10.1002/adhm.202102781 ↗
53. Humoral and cellular immunity of two-dose inactivated COVID-19 vaccination in Chinese children: A prospective cohort study10.1002/jmv.28380 ↗
54. Rough Nanovaccines Boost Antitumor Immunity Through the Enhancement of Vaccination Cascade and Immunogenic Cell Death Induction10.1002/smtd.202201595 ↗
55. The functions of autophagy at the tumour-immune interface10.1111/jcmm.16331 ↗
56. Enhancing Immunity with Nanomedicine: Employing Nanoparticles to Harness the Immune System10.1021/acsnano.0c08913 ↗
57. Abascal, J., Oh, M.S., Liclican, E.L., Dubinett, S.M., Salehi-Rad, R., and Liu, B. (2023). Dendritic Cell Vaccination in Non-Small Cell Lung Cancer: Remodeling the Tumor Immune Microenvironment. Cells, 12.10.3390/cells12192404 ↗
58. Heterologous prime-boost vaccination targeting MAGE-type antigens promotes tumor T-cell infiltration and improves checkpoint blockade therapy10.1136/jitc-2021-003218 ↗
59. Active immunization with a structurally aggregated PD-L1 antigen breaks T and B immune tolerance in non-human primates and exhibits in vivo anti-tumoral effects in immunocompetent mouse tumor models10.1016/j.canlet.2023.216156 ↗
60. Vaccination against galectin-1 promotes cytotoxic T-cell infiltration in melanoma and reduces tumor burden10.1007/s00262-021-03139-4 ↗
61. Anti-CD20 antibodies and bendamustine attenuate humoral immunity to COVID-19 vaccination in patients with B-cell non-Hodgkin lymphoma10.1007/s00277-023-05204-7 ↗
62. Multiple Nf1 Schwann cell populations reprogram the plexiform neurofibroma tumor microenvironment10.1172/jci.insight.154513 ↗
63. Waning Vaccine Immunity and Vaccination Responses in Children Treated for Acute Lymphoblastic Leukemia: A Canadian Immunization Research Network Study10.1093/cid/ciaa163 ↗
64. Therapeutische Immunisierungen gegen Tumore und neurodegenerative Erkrankungen [Therapeutic vaccination for tumors and neurodegenerative diseases]10.1007/s00103-020-03226-4 ↗
65. Chen, P.M., Pan, W.Y., Wu, C.Y., Yeh, C.Y., Korupalli, C., Luo, P.K., Chou, C.J., Chia, W.T., and Sung, H.W. (2020). Modulation of tumor microenvironment using a TLR-7/8 agonist-loaded nanoparticle system that exerts low-temperature hyperthermia and immunotherapy for in situ cancer vaccination. Biomaterials, 230.10.1016/j.biomaterials.2019.119629 ↗
66. Evaluating Anti-tumor Immune Responses of Protein Nanoparticle-Based Cancer Vaccines10.1007/978-1-0716-3222-2_18 ↗
67. Tumor-reactive T helper cells in the context of vaccination against glioma10.1016/j.ccell.2023.09.013 ↗
68. Nanotechnology-empowered vaccine delivery for enhancing CD8+ T cells-mediated cellular immunity10.1016/j.addr.2021.113889 ↗
69. Radiation to all macroscopic sites of tumor permits greater systemic antitumor response to in situ vaccination10.1136/jitc-2022-005463 ↗
70. Breast cancer vaccination: Latest advances with an analytical focus on clinical trials10.1016/j.intimp.2023.110696 ↗
71. Prophylactic Dendritic Cell Vaccination in Experimental Breast Cancer Controls Immunity and Hepatic Metastases10.21873/anticanres.15129 ↗
72. In Situ Tumor Vaccination with Nanoparticle Co-Delivering CpG and STAT3 siRNA to Effectively Induce Whole-Body Antitumor Immune Response10.1002/adma.202100628 ↗
73. Koeken, V.A.C.M., Qi, C., Mourits, V.P., de Bree, L.C.J., Moorlag, S.J.C.F.M., Sonawane, V., Lemmers, H., Dijkstra, H., Joosten, L.A.B., and van Laarhoven, A. (2022). Plasma metabolome predicts trained immunity responses after antituberculosis BCG vaccination. PLoS Biol., 20.10.1371/journal.pbio.3001765 ↗
74. Immunization with placenta-specific 1 (plac1) induces potent anti-tumor responses and prolongs survival in a mouse model of melanoma10.1016/j.advms.2022.08.002 ↗
75. Reprogramming the Canine Glioma Microenvironment with Tumor Vaccination plus Oral Losartan and Propranolol Induces Objective Responses10.1158/2767-9764.CRC-22-0388 ↗
76. Kostinov, M.P., Akhmatova, N.K., Karpocheva, S.V., Vlasenko, A.E., Polishchuk, V.B., and Kostinov, A.M. (2021). Vaccination Against Diphtheria and Tetanus as a Way to Activate Adaptive Immunity in Children with Solid Tumors. Front. Immunol., 12.10.3389/fimmu.2021.696816 ↗
77. Humoral and T-Cell Immune Response After 3 Doses of Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines in Fragile Patients: The Italian VAX4FRAIL Study10.1093/cid/ciac404 ↗
78. C5aR plus MEK inhibition durably targets the tumor milieu and reveals tumor cell phagocytosis10.26508/lsa.202302229 ↗
79. Temporary antimetabolite treatment hold boosts SARS-CoV-2 vaccination-specific humoral and cellular immunity in kidney transplant recipients10.1172/jci.insight.157836 ↗
80. Basement membrane proteins in extracellular matrix characterize NF1 neurofibroma development and response to MEK inhibitor10.1172/JCI168227 ↗
81. Research progress of vaccination status, efficacy and safety in children with tumor
82. Preclinical development of a vaccine-based immunotherapy regimen (VBIR) that induces potent and durable T cell responses to tumor-associated self-antigens10.1007/s00262-022-03245-x ↗
83. Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
84. An oral bait vaccination approach for the Tasmanian devil facial tumor diseases10.1080/14760584.2020.1711058 ↗
85. Reviving the role of MET in liver cancer therapy and vaccination: An autophagic perspective10.1080/2162402X.2020.1818438 ↗
86. Photoactivatable nanoagonists chemically programmed for pharmacokinetic tuning and in situ cancer vaccination10.1073/pnas.2210385120 ↗
87. Current Status and Challenges of Vaccination Therapy for Glioblastoma10.1158/1535-7163.MCT-22-0503 ↗
88. van Dam KP, J., Volkers, A.G., Wieske, L., Stalman, E.W., Kummer LY, L., van Kempen ZL, E., Killestein, J., Tas, S.W., Boekel, L., and Wolbink, G.J. (2023). Primary SARS-CoV-2 infection in patients with immune-mediated inflammatory diseases: Long-term humoral immune responses and effects on disease activity. BMC Infect. Dis., 23.10.1186/s12879-023-08298-6 ↗
89. COVID-19 Vaccination in Patients with Cancer and Patients Receiving HSCT or CAR-T Therapy: Immune Response, Real-World Effectiveness, and Implications for the Future10.1093/infdis/jiad174 ↗
90. Humoral Immunity After COVID-19 Vaccination in Chronic Lymphocytic Leukemia and Other Indolent Lymphomas: A Single-Center Observational Study10.1093/oncolo/oyad121 ↗
91. Intravenous Senescent Erythrocyte Vaccination Modulates Adaptive Immunity and Splenic Complement Production10.1021/acsnano.3c07943 ↗
92. Hartmann, A.K., Bartneck, J., Pielenhofer, J., Meiser, S.L., Arnold-Schild, D., Klein, M., Stassen, M., Schild, H., Muth, S., and Probst, H.C. (2023). Optimized dithranol-imiquimod-based transcutaneous immunization enables tumor rejection. Front. Immunol., 14.10.3389/fimmu.2023.1238861 ↗
93. COVID-19 vaccination: Evaluation of humoral and cellular immunity after the booster dose in chronic lymphocytic leukemia patients10.1002/hon.3121 ↗
94. Spatial delivery of immune cues to lymph nodes to define therapeutic outcomes in cancer vaccination10.1039/D2BM00403H ↗
95. Multifunctional nanoparticle potentiates the in situ vaccination effect of radiation therapy and enhances response to immune checkpoint blockade10.1038/s41467-022-32645-x ↗
96. Global Immunization Crisis Amid the COVID-19 Pandemic: Implications for Pediatric Oncology10.1200/GO.23.00477 ↗
97. Neoadjuvant in situ vaccination with cowpea mosaic virus as a novel therapy against canine inflammatory mammary cancer10.1136/jitc-2021-004044 ↗
98. In situ vaccination via tissue-targeted cDC1 expansion enhances the immunogenicity of chemoradiation and immunotherapy10.1172/JCI171621 ↗
99. Preventive cancer stem cell-based vaccination modulates tumor development in syngeneic colon adenocarcinoma murine model10.1007/s00432-022-04303-8 ↗
100. Combination Neoantigen-Based Dendritic Cell Vaccination and Adoptive T-Cell Transfer Induces Antitumor Responses Against Recurrence of Hepatocellular Carcinoma10.1158/2326-6066.CIR-21-0931 ↗